An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development.

Abstract:

:A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.

journal_name

Curr Pharm Des

authors

Chen S,Luo H,Chen L,Chen J,Shen J,Zhu W,Chen K,Shen X,Jiang H

doi

10.2174/138161206779010459

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

4539-53

issue

35

eissn

1381-6128

issn

1873-4286

journal_volume

12

pub_type

杂志文章,评审
  • Development of novel cardiovascular therapeutics from small regulatory RNA molecules--an outline of key requirements.

    abstract::Understanding of the roles of RNAs within the cell has changed and expanded dramatically during the past few years. Based on fundamentally new insights it is now increasingly possible to employ RNAs as highly valuable tools in molecular biology and medicine. At present, the most important therapeutic strategies are ba...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791792813

    authors: Poller W,Fechner H

    更新日期:2010-01-01 00:00:00

  • Modified polysaccharides as versatile materials in controlled delivery of antidegenerative agents.

    abstract::The mechanisms and factors causing or influencing degenerative diseases require tailor-made solutions. Natural polysaccharides are among the most versatile building units of the novel drug delivery systems. Their properties can be easily tailored to specific needs because they depend not only on the first-order struct...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212800492831

    authors: Karewicz A,Bielska D,Nowakowska M

    更新日期:2012-01-01 00:00:00

  • Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD).

    abstract::Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161210793797889

    authors: Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

    更新日期:2010-01-01 00:00:00

  • Treatment of disorders characterized by reversible airway obstruction in childhood: are anti-cholinergic agents the answer?

    abstract::Release of acetylcholine from parasympathetic nerves in the airways activates postjunctional muscarinic receptors present on smooth muscle, submucosal glands and blood vessels. This triggers bronchoconstriction, muscle hypertrophy, mucus secretion, and vasodilatation, respectively. The release of acetylcholine from pa...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811209023061

    authors: Quizon A,Colin AA,Pelosi U,Rossi GA

    更新日期:2012-01-01 00:00:00

  • In vitro modeling of the blood-brain barrier: simplicity versus complexity.

    abstract::Proper understanding of blood-brain barrier (BBB) regulation is crucial to reduce/prevent its disruption during injury. Since high brain complexity makes interpretation of in vivo data challenging BBB studies are frequently performed using simplified in vitro models. Although such models represent an important and fre...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797440159

    authors: Ogunshola OO

    更新日期:2011-01-01 00:00:00

  • Angiotensin II and Abdominal Aortic Aneurysms: An update.

    abstract::Abdominal aortic aneurysm (AAA) is a devastating disease associated with high prevalence of death due to aortic rupture. Currently the therapy is restricted to surgical procedures to prevent aortic rupture, which in turn has a risk for postoperative mortality. There are no proven pharmacological therapies available to...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150826093318

    authors: Liu J,Daugherty A,Lu H

    更新日期:2015-01-01 00:00:00

  • Targeted drugs and nanomedicine: present and future.

    abstract::Packaging small-molecule drugs into nanoparticles improves their bio-availability, bio-compatibility and safety profiles. Multifunctional particles carrying large drug payloads for targeted transport, immune evasion and favourable drug release kinetics at the target site, require a certain minimum size usually 30-300 ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787002870

    authors: Debbage P

    更新日期:2009-01-01 00:00:00

  • New therapies in cystic fibrosis.

    abstract::Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected patients. Lung disease is the major contributor to morbidity and mortality in patients with cystic fibrosis but recommende...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212799315984

    authors: Ratjen F,Grasemann H

    更新日期:2012-01-01 00:00:00

  • Particle design of membrane emulsification for protein drug and vaccine delivery.

    abstract::Biodegradable particles have important applications in Drug Delivery Systems (DDS) of protein/peptide drugs. And recently, particle systems have also showed to be powerful for vaccine delivery (adjuvant) in order to solve the difficulties when conventional Alum adjuvant was used. However, in above applications, the pr...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612821666150416100031

    authors: Wang L,Yang T,Ma G

    更新日期:2015-01-01 00:00:00

  • Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease.

    abstract::Statins effectively reduce cardiovascular disease (CVD) morbidity and mortality. However, even after low-density lipoprotein cholesterol goal attainment there is a residual CVD risk. To reduce this risk, combining statins with drugs acting on the renin-angiotensin system (RAS) was investigated. The GREek Atorvastatin ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140620115756

    authors: Athyros VG,Katsiki N,Karagiannis A,Mikhailidis DP

    更新日期:2014-01-01 00:00:00

  • Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.

    abstract::Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothel...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206778343046

    authors: Aversa A,Bruzziches R,Pili M,Spera G

    更新日期:2006-01-01 00:00:00

  • An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions.

    abstract::Drug hypersensitivity reactions (DHRs) represent a major burden on the healthcare system since their diagnostic and management are complex. As they can be influenced by individual genetic background, it is conceivable that the identification of variants in genes potentially involved could be used in genetic testing fo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191105122414

    authors: Mayorga C,Montañez MI,Jurado-Escobar R,Gil-Ocaña V,Cornejo-García JA

    更新日期:2019-01-01 00:00:00

  • Exploiting substrate recognition for selective inhibition of protein kinases.

    abstract::Protein kinases are potential targets of drugs to treat many human diseases. Intensive efforts have been made to develop protein kinase inhibitors, but a major challenge is achieving specificity. Exploiting regulatory elements outside the ATP binding pocket, such as the substrate binding site, may provide an alternati...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212800672741

    authors: Licht-Murava A,Eldar-Finkelman H

    更新日期:2012-01-01 00:00:00

  • Leptin: from animals to humans.

    abstract::Leptin has been shown to have a wide repertoire of peripheral effects, some of which are mediated through the central nervous system and others that are induced through a direct action on target tissues. There is now evidence showing that leptin exerts some of its metabolic effects acting directly on peripheral tissue...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033455369

    authors: Veniant MM,LeBel CP

    更新日期:2003-01-01 00:00:00

  • Rationale for Ras and raf-kinase as a target for cancer therapeutics.

    abstract::Improvements in our understanding of the intrinsic aberrancies in cancer cells have enabled the design and development of novel therapeutics that specifically target these changes. Among the many complex cellular pathways and mechanisms which have been unveiled by new molecular techniques, RAS-mediated signal transduc...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612023393107

    authors: Nottage M,Siu LL

    更新日期:2002-01-01 00:00:00

  • Beneficial effects of the Mediterranean diet on metabolic syndrome.

    abstract::The metabolic syndrome (MetS) represents a cluster of medical disorders, such as hyperglycemia, dyslipidemia, hypertension, and abdominal obesity that, when occurring together, increase the risk of developing cardiovascular disease. The role of food and nutrients in the aetiology of chronic diseases has become clearer...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612819666131206112144

    authors: Grosso G,Mistretta A,Marventano S,Purrello A,Vitaglione P,Calabrese G,Drago F,Galvano F

    更新日期:2014-01-01 00:00:00

  • Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease.

    abstract::Several diseases of the heart have been linked to an insufficient ability to generate enough energy (ATP) to sustain proper heart function. Hyperpolarized magnetic resonance (MR) is a novel technique that can visualize and quantify myocardial energy metabolism. Hyperpolarization enhances the MR signal from a biologica...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140417113720

    authors: Lauritzen MH,Sogaard LV,Madsen PL,Ardenkjaer-Larsen JH

    更新日期:2014-01-01 00:00:00

  • Antibiotic-resistant H. pylori infection and its treatment.

    abstract::Helicobacter pylori infection causes progressive damage to gastric mucosa and results in serious disease such as peptic ulcer disease, MALT lymphoma, or gastric adenocarcinoma in 20% to 30% of patients. The current approach is to make a firm diagnosis, give combination antibiotic and antisecretory therapy, and confirm...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612003399077

    authors: Graham DY,Qureshi WA

    更新日期:2000-10-01 00:00:00

  • Hypersensitivity reactions to iodinated contrast media.

    abstract::Adverse reactions after iodinate contrast media (ICM) administration have been observed, which can be classified as immediate (i.e., occurring within one hour after administration) and delayed or non-immediate (i.e., occurring more than one hour after administration). Even though the incidence of ICM adverse reactions...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206778193999

    authors: Guéant-Rodriguez RM,Romano A,Barbaud A,Brockow K,Guéant JL

    更新日期:2006-01-01 00:00:00

  • Depression in older persons with mobility limitations.

    abstract::The impact of depression on physical disability is undisputed. There is convincing evidence that depression increases the subsequent risk for physical disability and, in turn, physical disability results in increased depressive symptoms. Moreover, depression affects also the earlier stages of the disablement process (...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113196660060

    authors: Milaneschi Y,Penninx BW

    更新日期:2014-01-01 00:00:00

  • Current Perspectives Regarding Stem Cell-based Therapy for Ischemic Stroke.

    abstract::Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666180604111806

    authors: Kwak KA,Kwon HB,Lee JW,Park YS

    更新日期:2018-01-01 00:00:00

  • Angiotensin-converting enzyme inhibitors in veterinary medicine.

    abstract::Angiotensin-converting enzyme (ACE) inhibitors represent one of the most commonly used categories of drugs in canine and feline medicine. ACE inhibitors currently approved for use in veterinary medicine are benazepril, enalapril, imidapril and ramipril. They are all pro-drugs administered by oral route. A physiologica...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207780618830

    authors: Lefebvre HP,Brown SA,Chetboul V,King JN,Pouchelon JL,Toutain PL

    更新日期:2007-01-01 00:00:00

  • Inhibitors of tryptase for the treatment of mast cell-mediated diseases.

    abstract::Human tryptase is a structurally unique and mast cell specific trypsin-like serine protease. Recent biological and immunological investigations have implicated tryptase as a mediator in the pathology of numerous allergic and inflammatory conditions including rhinitis, conjunctivitis, and most notably asthma. A growing...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Rice KD,Tanaka RD,Katz BA,Numerof RP,Moore WR

    更新日期:1998-10-01 00:00:00

  • Cognition and Emotions in Recurrent Depressive Disorders - The Role of Inflammation and the Kynurenine Pathway.

    abstract::Separating emotions from cognition seems impossible in everyday experiences of a human being. Emotional processes have an impact on the ability of planning and solving problems, or decision-making skills. They are a valuable source of information about ourselves, our partners in interactions and the surrounding world....

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151230110738

    authors: Talarowska M,Galecki P

    更新日期:2016-01-01 00:00:00

  • Recent advances of fluorescent technologies for drug discovery and development.

    abstract::Recent progresses in the development of fluorescent technologies become a reliable device for drug discovery research. The fluorescence tools offer attractive options for an opportunity to visualize the effects of drug candidates in the cells. The fluorescent tools, such as fluorescent protein, are regularly used in a...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209789207006

    authors: Chakraborty C,Hsu CH,Wen ZH,Lin CS

    更新日期:2009-01-01 00:00:00

  • NAD in skin: therapeutic approaches for niacin.

    abstract::The maintenance and regulation of cellular NAD(P)(H) content and its influence on cell function involves many metabolic pathways, some of which remain poorly understood. Niacin deficiency in humans, which leads to low NAD status, causes sun sensitivity in skin, indicative of deficiencies in responding to UV damage. An...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787185760

    authors: Benavente CA,Jacobson MK,Jacobson EL

    更新日期:2009-01-01 00:00:00

  • Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update.

    abstract::The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes o...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666190717104547

    authors: Usman B,Sharma N,Satija S,Mehta M,Vyas M,Khatik GL,Khurana N,Hansbro PM,Williams K,Dua K

    更新日期:2019-01-01 00:00:00

  • Apolipoprotein E knockout models.

    abstract::Atherosclerosis is a multifactorial and long-lasting process in humans. Therefore, animal models where more rapid changes occur can be useful for the study of this process. Among such models are the apolipoprotein (apo) E knock out mice. Apo E deficient mice show impaired clearing of plasma lipoproteins and they devel...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208783497769

    authors: Kolovou G,Anagnostopoulou K,Mikhailidis DP,Cokkinos DV

    更新日期:2008-01-01 00:00:00

  • AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?

    abstract::Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612024607135

    authors: Weiser T

    更新日期:2002-01-01 00:00:00

  • A Review on Cancer Therapy Based on the Photothermal Effect of Gold Nanorod.

    abstract:BACKGROUND:Cancer causes millions of deaths and huge economic losses every year. The currently practiced methods for cancer therapy have many defects, such as side effects, low curate rate, and discomfort for patients. OBJECTIVE:Herein, we summarize the applications of gold nanorods (AuNRs) in cancer therapy based on ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191216150052

    authors: Xu W,Lin Q,Yin Y,Xu D,Huang X,Xu B,Wang G

    更新日期:2019-01-01 00:00:00